Pomerantz LLP Initiates Class Action Litigation Against AeroVironment, Inc. – AVAV

Pomerantz LLP filed a securities class action against AeroVironment (AVAV) and certain officers, alleging violations of Sections 10(b) and 20(a) / Rule 10b-5. During the alleged period, AeroVironment faced a BADGER/SCAR stop-work order, followed by contract termination and an FY26 Q3 third-quarter operating loss of $179.0M (vs. $3.1M a year earlier) including a $151.3M goodwill impairment, and the stock fell sharply on multiple related dates (-15.77% on Jan 20, -17.42% on Mar 2, and -6.24% on Mar 11). The suit also claims the company overstated growth prospects related to the Space Force’s SCAR modernization efforts.

Analysis

The real damage is not the lawsuit itself; it is the market learning that a previously “story-stock” revenue bridge may have been a single-source option rather than an annuity. That shifts AVAV from a high-multiple, program-concentration name into a classic defense execution-risk situation where backlog quality matters more than headline growth, and every delay in the recompete raises the discount rate applied to near-term earnings. Expect the first leg to be multiple compression rather than another fundamental haircut.

The second-order winners are less the obvious primes and more any supplier exposed to a lower-cost, commercialized procurement model: names with modular antenna, RF, and ground-station content should gain share if the customer prefers multi-vendor sourcing. In practice, that favors larger diversified contractors with procurement reach and price discipline, while a bespoke, single-program specialist like AVAV faces a weaker negotiating position and possible margin dilution if it wins back work under tighter terms. The impairment also flags that acquisition-era synergy assumptions may need to be reset, which can spill over into further goodwill/earnings quality skepticism.

Catalyst path: in days, litigation headlines keep a governance overhang in place; in 1-3 months, any docket disclosures, revised government acquisition language, or contracting cadence will drive the next move; over 6-18 months, the key is whether SCAR becomes a lower-margin, multi-award architecture. The contrarian view is that the stock may not be fully reflecting the probability of AVAV participating in some form of the program, but the burden of proof is now on management to show lost sole-source economics are replaceable. What falsifies the bearish thesis: a clean recompete outcome with preserved margins or a disclosure that SCAR was immaterial to forward revenue.

Key Decisions for Investors

• Short AVAV on rallies over the next 1-3 weeks; prefer strength into legal-news pop versus chasing weakness. Risk/reward skews favorably unless management can quickly quantify SCAR as non-material.
• Buy AVAV put spreads for the next earnings/legal window (1-3 months) to express further multiple compression while capping premium outlay. Falsify on any announcement of a favorable recompete or restored delivery schedule.
• Pair trade: long a diversified defense prime basket (LHX/NOC/RTX) vs short AVAV for 3-6 months. Thesis: procurement diversifies to vendors with broader contracting leverage while AVAV faces program-specific de-rating.
• Watch for a broad aerospace/defense supplier read-through rather than AVAV alone; if the Space Force explicitly favors COTS, rotate toward names with recurring ground-system content and away from bespoke development exposure.
• Set an alert on AVAV around the next government filing or guidance update: if SCAR-related revenue is still being guided as meaningful after the contract termination, that would increase the probability of further downside.